{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:39:23Z","timestamp":1760985563507},"reference-count":17,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,8,1]]},"abstract":" PURPOSE: Although the improved overall survival (OS) of patients who receive Canvaxin (CancerVax Corp, Carlsbad, CA) polyvalent vaccine (PV) immunotherapy for metastatic melanoma has been correlated with cellular and humoral immune responses, the mechanisms of vaccine immunotherapy for early-stage melanoma are unclear. Specific immune responses to tumor-associated antigens might correlate with disease-free survival (DFS) and OS in patients receiving adjuvant PV therapy for primary melanoma. <\/jats:p> PATIENTS AND METHODS: Eighty-three patients received PV plus bacille Calmette-Gu\u00e9rin after wide excision of American Joint Committee on Cancer stage II melanoma. Humoral and cellular responses during the first 12 weeks of adjuvant immunotherapy were assessed by serum antibody titers to a tumor-associated 90-kd glycoprotein antigen (TA90) expressed by PV, and by delayed-type hypersensitivity (DTH) skin testing with PV (PV-DTH). <\/jats:p> RESULTS: At a median follow-up period of 46.6 months (range, 10.7 to 93.6 months), an increased PV-DTH response seemed to be associated with improved 5-year DFS (54% v 20%) and 5-year OS (75% v 60%), but the correlations were not statistically significant. Anti-TA90 immunoglobulin (Ig) M levels \u2265 1:800 were significantly correlated with improved 5-year DFS and improved 5-year OS, and multivariate analysis identified anti-TA90 IgM as an independent prognostic factor for OS and DFS. <\/jats:p> CONCLUSION: These findings suggest that an increased IgM response in patients receiving PV therapy for stage II melanoma is associated with decreased recurrence and improved survival. <\/jats:p>","DOI":"10.1200\/jco.2002.01.065","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T08:15:05Z","timestamp":1487924105000},"page":"3242-3248","source":"Crossref","is-referenced-by-count":50,"title":["Enhanced Humoral Immune Response Correlates With Improved Disease-Free and Overall Survival in American Joint Committee on Cancer Stage II Melanoma Patients Receiving Adjuvant Polyvalent Vaccine"],"prefix":"10.1200","volume":"20","author":[{"given":"L. Andrew","family":"DiFronzo","sequence":"first","affiliation":[{"name":"From the Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories of the John Wayne Cancer Institute at Saint John\u2019s Health Center, Santa Monica, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishab K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"From the Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories of the John Wayne Cancer Institute at Saint John\u2019s Health Center, Santa Monica, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Essner","sequence":"additional","affiliation":[{"name":"From the Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories of the John Wayne Cancer Institute at Saint John\u2019s Health Center, Santa Monica, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leland J.","family":"Foshag","sequence":"additional","affiliation":[{"name":"From the Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories of the John Wayne Cancer Institute at Saint John\u2019s Health Center, Santa Monica, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"O\u2019Day","sequence":"additional","affiliation":[{"name":"From the Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories of the John Wayne Cancer Institute at Saint John\u2019s Health Center, Santa Monica, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie A.","family":"Wanek","sequence":"additional","affiliation":[{"name":"From the Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories of the John Wayne Cancer Institute at Saint John\u2019s Health Center, Santa Monica, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey L.","family":"Stern","sequence":"additional","affiliation":[{"name":"From the Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories of the John Wayne Cancer Institute at Saint John\u2019s Health Center, Santa Monica, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald L.","family":"Morton","sequence":"additional","affiliation":[{"name":"From the Sonya Valley Ghidossi Vaccine Laboratory of the Roy E. Coats Research Laboratories of the John Wayne Cancer Institute at Saint John\u2019s Health Center, Santa Monica, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-108369","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.5.1036"},{"key":"R2-108369","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512053132327"},{"key":"R3-108369","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199210000-00010"},{"key":"R4-108369","unstructured":"DiFronzo LA, Morton DL: Melanoma vaccines: Current status of clinical trials. Adv Oncol 16: 23,2000-29,"},{"key":"R5-108369","unstructured":"Shen P, Foshag LJ, Essner R, et al: Postoperative adjuvant therapy using a polyvalent melanoma vaccine improves overall survival of patients with primary melanoma. Proc Am Soc Clin Oncol 18: 533a,1999 (abstr 2059)"},{"key":"R6-108369","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1176"},{"key":"R7-108369","unstructured":"Gupta RK: Circulating immune complexes in malignant melanoma. Dis Markers 6: 81,1988-96,"},{"key":"R8-108369","doi-asserted-by":"crossref","unstructured":"Euhus DM, Gupta RK, Morton DL: Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 29: 247,1989-254,","DOI":"10.1007\/BF00199212"},{"key":"R9-108369","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2913"},{"key":"R10-108369","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.1860060514"},{"key":"R11-108369","doi-asserted-by":"publisher","DOI":"10.1007\/BF02305761"},{"key":"R12-108369","doi-asserted-by":"crossref","unstructured":"Bystryn J-C, Oratz R, Roses D, et al: Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69: 1157,1992-1164,","DOI":"10.1002\/cncr.2820690516"},{"key":"R13-108369","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.11.1858"},{"key":"R14-108369","unstructured":"Barth A, Hoon DSB, Foshag LJ, et al: Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 54: 3342,1994-3345,"},{"key":"R15-108369","unstructured":"Jones PC, Sze LL, Liu PY, et al: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen (OFA-1). J Natl Cancer Inst 66: 249,1981-254,"},{"key":"R16-108369","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.9.4498"},{"key":"R17-108369","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199601000-00007"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.01.065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:47:35Z","timestamp":1653515255000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.01.065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,1]]},"references-count":17,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2002,8,1]]}},"alternative-id":["10.1200\/JCO.2002.01.065"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.01.065","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,1]]}}}